Clinical Utility of ctDNA in the Treatment of Oligometastatic Disease
ConditionOligometastatic Cancer
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAarhus University Hospital
About this trial
This prospective observational study investigates the clinical utility of circulating tumor DNA (ctDNA) in patients with oligometastatic disease (OMD) undergoing definitive-intent local ablative treatment (LAT). The study aims to evaluate ctDNA as a prognostic and response biomarker before, during, and after LAT across cancer types and treatment modalities. Serial plasma samples and archival tumor tissue will be analyzed to assess ctDNA detection rates, elimination patterns, minimal residual disease, and association with recurrence, progression, and survival outcomes.
Eligibility criteria
Qualifiers
Metastatic spread from histopathological diagnosed solid cancer
Planned for LAT (local ablative therapy) for OMD (oligometastatic disease)
≥ 18 years
Written and oral consent
Disqualifiers
Other cancer disease within 5 years
Conditions that will contraindicate blood samples
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov